파이프라인
한미약품은 축적된 연구 개발 기술력을 바탕으로 비만 및 대사성 질환, 항암, 희귀질환 치료제 분야에서
다양한 혁신신약을 개발하고 있습니다.

주요 파이프라인 소개

한미약품과 인류의 건강을 위한 창조와 혁신 그리고 도전 정신을 함께 할 파트너사를 찾습니다.

BH3120 (PD-L1/4-1BB BsAb)

OVERVIEW

BH3120 is a heterodimeric bispecific antibody (PENTAMBODY) designed to target 4-1BB and PD-L1 simultaneously to stimulate anti-tumor immune response either by inhibition of an immune checkpoint mechanism and by activation of a co-stimulatory signal in tumor microenvironment (TME) focused manner.

Non-clinical observations with BH3120, either as a monotherapy or in combination settings, consistently explain strong anti-tumor T cell activities in tumor tissue specific manner with clear dose dependency, while systemic immune response is minimally modulated.

These properties support further evaluation of the immune-modulating bispecific antibody, and BH3120 will be studied as a therapeutic candidate with multiple types of solid tumors.
Dual cancer
immunotherapy
targets
  • Inhibition of PD-1/PD-L1, T cell- co-stimulatory signaling by 4-1BB agonism
  • Conditional, PD-L1 binding dependent, 4-1BB activation in tumor tissue specific manner
  • Well balanced efficacy and safety in mono and combination settings

PUBLICATIONS

BH3120, a bispecific antibody targeting 4-1BB and PD-L1 simultaneously, stimulates T cells in tumor tissue preferred manner
Poster, American Association for Cancer Research (AACR) 114th Annual meeting, 2023
BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles
Poster, American Association for Cancer Research (AACR) 113th Annual meeting, 2022